The Antwerp Commercial Court dismissed Merck's claim for injunctive relief against Teva, ruling that Teva's montelukast-based generic medicines do not infringe Merck's European patent (EP 0 737 186)…
In this judgment the Barcelona Court of Appeal concluded that any ‘preparatory acts’ (for example, submitting samples) conducted prior to the introduction in Spain of the ‘Bolar Clause’, as required…
The District Court of The Hague finds that the generic products of the defendants fall under the scope of protection of both of Mundipharma's patents, which are related to controlled release…
In these infringement proceedings before the Preliminary Relief Judge of the District Court of The Hague the defendant argued that the claimants should not have received an SPC for valaciclovir,…
The Bulgarian Patent Office (BPO) revoked patent BG 61365 and published an announcement of the revocation in its official bulletin. The revocation was appealed by AstraZeneca Pharmaceuticals LR. The…
The Administrative Law Division of the Council of State holds that the District Court has rightfully found that the Patent Office was not obligated to issue a Supplementary Protection Certificate for…
The Federal Court of Justice ruled that the subject matter of a patent does not extend beyond the content of the application as filed when terms are used in the claims that are not literally used in…
The Court of Appeal has overturned the High Court's finding of non-infringement, holding Napp's divisional patents, relating to controlled release formulations of a painkiller called oxycodone, to be…
